Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 1
2007 2
2008 2
2009 2
2010 8
2011 1
2012 4
2013 4
2014 5
2015 7
2016 10
2017 14
2018 10
2019 7
2020 14
2021 2
2022 7
2023 11
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Results by year

Filters applied: . Clear all
Page 1
UGDH promotes tumor-initiating cells and a fibroinflammatory tumor microenvironment in ovarian cancer.
Harrington BS, Kamdar R, Ning F, Korrapati S, Caminear MW, Hernandez LF, Butcher D, Edmondson EF, Traficante N, Hendley J; Australian Ovarian Cancer Study; Gough M, Rogers R, Lourie R, Shetty J, Tran B, Elloumi F, Abdelmaksoud A, Nag ML, Mazan-Mamczarz K, House CD, Hooper JD, Annunziata CM. Harrington BS, et al. Among authors: annunziata cm. J Exp Clin Cancer Res. 2023 Oct 19;42(1):270. doi: 10.1186/s13046-023-02820-z. J Exp Clin Cancer Res. 2023. PMID: 37858159 Free PMC article.
A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma.
Atkins SLP, Greer YE, Jenkins S, Gatti-Mays ME, Houston N, Lee S, Lee MJ, Rastogi S, Sato N, Burks C, Annunziata CM, Lee JM, Nagashima K, Trepel JB, Lipkowitz S, Zimmer AS. Atkins SLP, et al. Among authors: annunziata cm. Oncologist. 2023 Oct 3;28(10):919-e972. doi: 10.1093/oncolo/oyad164. Oncologist. 2023. PMID: 37279797 Free PMC article. Clinical Trial.
Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.
Cole CB, Morelli MP, Fantini M, Miettinen M, Fetsch P, Peer C, Figg WD, Yin T, Houston N, McCoy A, Lipkowitz S, Zimmer A, Lee JM, Pavelova M, Villanueva EN, Trewhitt K, Solarz BB, Fergusson M, Mavroukakis SA, Zaki A, Tsang KY, Arlen PM, Annunziata CM. Cole CB, et al. Among authors: annunziata cm. J Exp Clin Cancer Res. 2023 Apr 26;42(1):102. doi: 10.1186/s13046-023-02668-3. J Exp Clin Cancer Res. 2023. PMID: 37101182 Free PMC article. No abstract available.
First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.
Cole CB, Morelli MP, Fantini M, Miettinen M, Fetsch P, Peer C, Figg WD, Yin T, Houston N, McCoy A, Lipkowitz S, Zimmer A, Lee JM, Pavelova M, Villanueva EN, Trewhitt K, Solarz BB, Fergusson M, Mavroukakis SA, Zaki A, Tsang KY, Arlen PM, Annunziata CM. Cole CB, et al. Among authors: annunziata cm. J Exp Clin Cancer Res. 2023 Mar 29;42(1):76. doi: 10.1186/s13046-023-02649-6. J Exp Clin Cancer Res. 2023. PMID: 36991390 Free PMC article. Clinical Trial.
Correction: Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial.
Green DS, Ning F, Duemler A, Myers TG, Trewhitt K, Ekwede I, McCoy A, Houston N, Lee JM, Lipkowitz S, Zimmer A, Pavelova M, Villanueva EN, Smith L, Blakely A, Casablanca Y, Highfill SL, Stroncek DF, Collins-Johnson N, Panch S, Procter J, Pham C, Korrapati S, Holland SM, Rosen LB, Nunes AT, Zoon KC, Cole CB, Annunziata CM. Green DS, et al. Among authors: annunziata cm. Clin Cancer Res. 2023 Jan 17;29(2):501. doi: 10.1158/1078-0432.CCR-22-3833. Clin Cancer Res. 2023. PMID: 36647676 No abstract available.
102 results